Pharma-Bio Serv reports recurring updates as an OTCQB-traded consulting firm providing regulatory affairs, quality, compliance, project management and technology-transfer support to pharmaceutical, biotechnology, chemical, medical device, cosmetic, food and allied products industries. Company announcements primarily cover quarterly and annual operating results, revenue and net income trends, service-portfolio adjustments, cost-structure discipline, client and project activity, and special cash dividends approved by the board.
Pharma-Bio Serv (OTCQB:PBSV), a consulting firm serving various industries including pharmaceuticals, announced a revenue decline for the three and six months ending April 30, 2024. Revenues were $2.4 million and $4.8 million, respectively, marking a decrease of $2.2 million and $4.0 million compared to the same periods last year. The company reported a net loss of $0.2 million and $0.5 million for these periods, compared to net income of $0.4 million and $0.8 million in the previous year. Despite these setbacks, the company is investing in new client relationships and global events to foster growth and stability in the future.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Pharma-Bio Serv, Inc. (OTCQB:PBSV) reported revenue of approximately $4.2 million for the quarter ending January 31, 2023, marking a decrease of $0.8 million year-over-year. However, net income rose to $0.4 million, an increase of $0.1 million compared to the previous year. The CEO, Mr. Sanchez, emphasized the strategic focus on more profitable markets, resulting in improved gross profit percentages. The company operates in markets including Puerto Rico, the US, Europe, and Latin America, providing regulatory compliance consulting services across various industries.
Pharma-Bio Serv (OTCQB:PBSV) has announced a Special Dividend of $0.075 per share, payable on or about April 14, 2023. This dividend is for shareholders of record as of the close of business on March 29, 2023. The company offers consulting services in regulatory compliance to various industries, including pharmaceuticals and biotechnology, mainly in Puerto Rico, the United States, Europe, and Latin America. The announcement reflects the company's commitment to returning value to its shareholders.
Pharma-Bio Serv (OTCQB:PBSV), a consulting firm in regulatory compliance, announced its partnership with ACP Capital Markets LLC for investment banking and M&A advisory services. This collaboration is aimed at strategically growing the company through potential acquisitions and enhancing shareholder value. CEO Victor Sanchez expressed optimism about working with ACP, highlighting their M&A expertise. Pharma-Bio Serv's services span across the pharmaceutical and biotechnology sectors, serving markets in Puerto Rico, the U.S., Europe, and Latin America. The company emphasizes regulatory compliance consulting, supported by a skilled global team.
Pharma-Bio Serv, Inc. (OTCQB:PBSV) reported fiscal year 2022 revenues of approximately $19.4 million, a decrease of $0.7 million compared to the previous year. However, net income improved to approximately $1.0 million, reflecting a $3.0 million increase year-over-year, influenced by a prior year's $5.2 million account receivable provision and $2.0 million PPP loan forgiveness. CEO Mr. Sanchez highlighted growth in the continental U.S. and European markets as a foundation for future expansion and strategic acquisitions aimed at maximizing shareholder value.